Accelerate Your U.S. OTC Skincare Portfolio with Raphas’s Proven Patch Solutions

Turnkey FDA-compliant OTC patch solutions engineered for scalable, high-volume production.

Dear Valued Partners,

Raphas is pleased to introduce our expanded line of U.S. FDA-compliant OTC topical patches. 

Backed by our specialized manufacturing capabilities, we are actively driving the commercialization of turnkey OTC patch solutions designed for the U.S. skincare market.

As the world’s first microneedle patch manufacturer to successfully pass an FDA OTC Audit, 

Raphas has consistently demonstrated compliance with rigorous cGMP quality control and pharmaceutical-grade manufacturing standards.

1Proven Market Success: OTC Microneedle Patches

Building on our robust manufacturing expertise, our OTC Microneedle Patch launched in 2023 has achieved remarkable market traction:

• 2 Million+ Units Distributed: Sustained, upward sales growth entering its third year in the U.S. market.
• Validated Performance: Demonstrated consumer demand and proven commercial viability in the competitive U.S. OTC space.

 

2Next-Gen Innovation: OTC Hydrocolloid Dot Patches

We are proud to launch our latest breakthrough—the OTC Hydrocolloid Dot Patch. 

While hydrocolloid patches are ubiquitous in acne care, 

developing them as FDA-compliant OTC drug products requires an advanced level of design and quality engineering.

• Concentrated Active "DOT" Technology: Unlike conventional patches that simply blend active ingredients into an adhesive matrix, 
• Raphas engineered a concentrated "DOT" core of active OTC drug ingredients. 
• This ensures direct active-to-skin contact, enabling significantly faster absorption and superior target delivery.
• 
  
• High-Volume Cost Efficiency: Delivers validated pharmaceutical quality at a highly competitive unit cost, 
• allowing for scalable, high-volume production without compromising efficacy.

 

3Versatile Formulations & Seamless Market Entry

While our flagship OTC patches are optimized for acne treatment, our technology platform is fully customizable:

• Multi-Benefit Expansion: Tailored formulation development available for targeted indications, 
• including brightening (hyperpigmentation) and anti-itch/soothing.
• Lower Barrier to Entry: Bypass costly regulatory hurdles, extended timelines, and development risks 
• by leveraging our FDA-audited manufacturing infrastructure and regulatory track record.

Partner with Raphas

We invite you to explore the commercial potential of our OTC patch formulations. Please visit our B2B partner site for technical details.

To discuss product specifications, custom ODM terms, MOQs, or packaging options, contact our team today for a tailored consultation. Let’s expand your inventory with high-efficacy, cost-competitive OTC solutions.

Thank you.

Raphas ODM Sales Team